Clinical trials: ADHD Predominantly Inattentive Type
ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of MG01CI (1400 mg daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with ADHD.
- Trial name
- NCT02059642
- Testing
- MG01CI (1400 mg)
- Where
- 20 sites in United States, Israel
- Volunteers
- 300 people
- Sponsor
- Alcobra Ltd.